Borrowings

The Company had $39.0 million and $38.7 million of outstanding debt, net of debt discounts, as of December 31, 2018 and December 31, 2017, respectively.

Term Loan

In August 2016, the Company entered into a Term Loan facility and a revolving line of credit with Silicon Valley Bank, or SVB and Oxford Finance LLC, or Oxford for $35.2 million. The Term Loan had interest only periods for six months up to October 1, 2017 and was then to be repaid over 25 months of equal principal payments plus interest. The maturity date of the term loan was December 1, 2019, and it carried an interest rate equal to the greater of 11% or the WSJ Prime rate plus 7.75%. The Term Loan borrowings were senior unsecured obligations of the Company, ranking equally and ratably among themselves and with the Company’s existing and future unsecured and unsubordinated debt.

In conjunction with the above Term Loan agreement, the Company issued redeemable convertible preferred stock warrants (refer to Note 9 for details).

In October 2017, the Company extinguished the Term Loan with SVB and Oxford. Concurrently, the Company entered into a New Term Loan with Pharmakon Advisors, or Pharmakon. As a result of the extinguished debt, the Company paid $29.1 million in principal payments to SVB and Oxford. The Company also paid $1.5 million in early termination fees and recorded $0.7 million of unamortized debt discounts. This loss on extinguishment of $2.2 million is reflected as interest expense in the consolidated statement of operations.

The Company entered into the New Term Loan with Pharmakon for $40.0 million in October 2017. Debt issuance costs of $1.3 million were recorded as a direct deduction from the carrying amount of the New Term Loan on the consolidated balance sheet, and are being amortized over the period of the New Term Loan using the effective interest method to interest expense in the consolidated statement of operations. The New Term Loan includes an interest-only period for 35 months through September 2020 and is then repaid in equal quarterly principal payments plus interest through December 2022, and is classified as long-term borrowings on the consolidated balance sheet. The New Term Loan carries a fixed interest rate of 11.5% and a closing fee of 1.5% of the funded amount, or $0.6 million. The New Term Loan includes a pre-payment fee equal to the interest due for the first 30 months of the agreement if it is prepaid within the first 30 months, a 2% prepayment penalty for months 31-48, and a 1% penalty for months 49-60. The New Term Loan required the Company to maintain a minimum cash balance of $5.0 million and to achieve certain revenue targets through December 31, 2018. Beginning with the three months ended March 31, 2019, the Company is required to meet either revenue or earnings targets. Under the New Term Loan, the Company also has a second tranche of $10.0 million available through January 2019, contingent upon the achievement of certain revenue milestones. The Company did not draw upon the second tranche. The New Term Loan is a senior obligation secured with a blanket first lien on the assets of the Company. As of December 31, 2018 and December 31, 2017, the total loan balance, net of debt discount, was $39.0 million and $38.7 million, respectively, with an effective interest rate of 12.3% and 12.0%, respectively, and the Company was in compliance with all debt covenants.

Approximate annual future minimum principal payments under the loan agreements as of December 31, 2018 are as follows (in thousands):



Year Ending at, December 31,
2019	$	—
2020	4,444
2021	17,778
2022	17,778
Total future minimum payments	40,000
Less:
Amount representing debt discount	(1,037		)
Total minimum payments	$	38,963

The New Term Loan required the Company to maintain a minimum cash balance of $5.0 million and to achieve certain revenue targets, which we were in compliance with through December 31, 2018.

Beginning with the three months ended March 31, 2019, the Company is required to meet either minimum net sales or trailing 12-month consolidated EBITDA targets. The Company needs to meet one or the other, but not both. If the Company does not meet either the minimum net sales or trailing 12-month consolidated EBITDA targets, the debt will immediately become due. The minimum net sales and trailing 12-month consolidated EBITDA targets are as follows (in thousands):



Twelve Months Ending	Minimum Net Sales			Trailing 12-Month Consolidated EBITDA
March 31, 2019	$	52,000	or	$	(5,000	)
June 30, 2019	$	53,500	or	$	(3,500	)
September 30, 2019	$	54,500	or	$	(2,000	)
December 31, 2019	$	56,000	or	$	—
March 31, 2020	$	57,500	or	$	1,000
June 30, 2020	$	58,500	or	$	2,000
thereafter, as applicable	$	60,000	or	$	3,000

The New Term Loan is collateralized by all of the Company's assets, including intellectual property.

Through December 31, 2018, the Company was in compliance with all of its debt obligations and covenants.

Line of Credit

In October 2015, the Company entered into an agreement with its existing lender SVB and Oxford. The amount of the revolving line of credit was $4.0 million (or 80% of the amount of certain customer accounts receivable). It carried an interest rate equal to the WSJ Prime rate plus 3% with a maturity of December 1, 2019. In October 2017, this line of credit was cancelled in conjunction with the SVB and Oxford debt extinguishment discussed above. No draws were made on this facility through its cancellation.